This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Chapter 24
Fachinformation Zyloric (2013): http://www.fachinfo.de/suche/fi/002332 (abgerufen 27.06.2014)
Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, tonelli M (2013): A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43: 367–375
Janssens H, Lucassen P, Van de Laar F, Janssen M, Van de Lisdonk E (2008): Systemic corticoster- oids for acute gout. Cochrane Database Syst Rev. 2008 Apr 16; (2): CD005521 Lin KC, Lin HY, Chou P (2000): Community based epidemiological study on hyperuricemia and gout in Kin-Hou. J Rheumatol 27: 1045–1050
Löffler W, Simmonds HA, Gröbner W (1983): Gout and uric acid nephropathy: Some new as- pects in diagnosis and treatment. Klin Wochenschr 61: 1223–1239
Love BL, Barrons R, Veverka A, Snider KM (2010): Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 30: 594–608
Neogi T (2011): Clinical practice. Gout. N Engl J Med 364: 443–452
NN (2014): Bei asymptomatischer Hyperurikämie wird zu häufig Allopurinol verordnet. Arzneimittelbrief 48: 46–47
Pasina L, Brucato AL, Djade CD, Di Corato P, Ghindoni S, Tettamanti M, Franchi C, Salerno F, Corrao S, Marcucci M, Mannucci PM, Nobili A (2014): Inapprobiate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry. Eur J Clin Pharmacol 70: 1495–1503
Sundy JS (2010): Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 22: 188–193
Suresh E, Das P (2012): Recent advances in management of gout. QJM 105: 407–417
Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012): Febuxostat for treating chronic gout.
Cochrane Database Syst Rev. 2012 Nov 14; 11: CD008653 Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentäo J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006a): EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1301–1311
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentäo J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006b): EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1312132–4
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mühlbauer, B., Schmidt, G. (2015). Gichtmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_24
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)